ROLE OF DEGARELIX (FIRMAGON) IN THE TREATMENT OF DISSEMINATED PROSTATE CANCER: CAN THE QUALITY OF CASTRATION THERAPY BE IMPROVED?
<p>Degarelix (Firmagon) (Ferring Pharmaceuticals) is a new gonadotropin-releasing hormone (GnRH) antagonist permitted and approved for use in the treatment of hormone-dependent prostate cancer. It is recommended to administer the drug subcutaneously in the abdomen in a starting dose of 240 mg,...
Main Authors: | , |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2014-07-01
|
Series: | Onkourologiâ |
Subjects: | |
Online Access: | http://oncourology.abvpress.ru/index.php/oncur/article/view/107 |